See more
Is Baxalta same as Baxter?
Baxalta (Bax from the name of its former parent company; alta a Latin adjective meaning 'high' or 'profound') is a biopharmaceutical company founded on 1 July 2015 after its parent company, Baxter International, spun off biopharmaceutical division.
What does Baxalta do?
Baxalta Incorporated (NYSE: BXLT) is a $6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology.
Is Baxalta part of Takeda?
Baxalta was a unit of Shire at the time, but the company was later acquired by Japanese drugmaker Takeda, which was then stuck with the bill.
When did Baxalta spin off from Baxter?
July 2015Those transactions most recently include the July 2015 spin-off of Baxalta Incorporated (which was subsequently acquired by Shire plc).
Did Shire acquire Baxalta?
Baxalta shareholders will receive a combination of $18.00 in cash and 0.1482 Shire ADS's for each Baxalta share (or 0.4446 of a Shire ordinary share if the Baxalta shareholder validly elected to receive ordinary shares);...FOR SHIRERobert Stanislaro (New York)[email protected]+1 212 850 560013 more rows•Jun 2, 2016
Does Takeda own Shire?
Takeda Completes Acquisition of Shire, Becoming a Global, Values-based, R&D-Driven Biopharmaceutical Leader. Corporate Governance Values and Corporate Governance Board of Directors Nomination Committee and Compensation Committee Audit and Supervisory Committee and Internal Audit Our Management Charters and Reports, etc ...
Who bought Baxalta?
After a courtship of more than six months, Shire won over its fellow drug maker Baxalta on Monday in a deal valued at about $31 billion. The combination would create a giant in the treatment of rare diseases.
What does Takeda Pharmaceuticals make?
With over 30 manufacturing sites spanning the globe, Takeda manufactures medicine for patients on 4 platforms: Small Molecules, Biologics, Plasma and Cell and Gene.
Who owns Shire Pharmaceuticals?
Takeda Pharmaceutical CompanyShire / Parent organizationThe Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue. Wikipedia
How much did Takeda pay for Shire?
$62bnThe deal was worth $62bn, making it Japan's largest foreign acquisition to date, by a significant margin and one of the largest pharmaceutical deals of the 21st century; Informa Pharma Intelligence ranks it as the fifth largest biopharma mergers and acquisitions (M&A) deal in history.
When was Baxalta founded?
Baxalta ( Bax from the name of its former parent company; alta a Latin adjective meaning 'high' or 'profound') is a biopharmaceutical company founded on 1 July 2015 after its parent company, Baxter International, spun off biopharmaceutical division.
What was the Baxalta offer in 2015?
In August 2015, Shire Plc made an unsolicited $30.6 billion stock offer for the company increasing the Baxalta share price over 16%. Baxalta investors would be set to receive 0.1687 of Shire's American Depositary Receipts for every share they hold, representing a premium of 36%, compared to the company's stock price on August 3. This deal would create the largest global biotech company focused solely on rare diseases.
Where is Baxalta located?
US-based biopharmaceutical company Baxalta, a spin-off of Baxter International, began building a biologics facility in Georgia, US, in August 2012.
What is Baxalta focusing on?
Baxalta focuses on the unmet needs of patients who require these therapies for a long time.
What is the name of the immunoglobulin therapy that Baxalta sells?
The licensed immunoglobulin therapy currently marketed by Baxalta in the US and Canada is the Gammagard Liquid . This is used to treat patients with primary immunodeficiency and is marketed under the name Kiovig outside the US and Canada.
Where is the biotech training center in Georgia?
A biotech training centre in Stanton Springs operated by Georgia Quick Start, a customised workforce training programme, will provide technically trained personnel for Baxalta and other biopharmaceutical companies in the state.
What is Baxalta biopharmaceutical?
Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia , immunology and oncology .
Who are the competitors of Baxalta?
Competitors of Baxalta include Novartis, Pfizer and Roche.
Media Related Inquiries
For media inquiries or reporter requests for more information, contact our Corporate Communications via [email protected].
Main Addresses
Our U.S. Hub in Massachusetts is the operational center for the U.S. commercial business unit, Global R&D, Global Oncology, Global Vaccines, and biologics manufacturing. There are several buildings across Lexington and Cambridge, MA, the main address for US are:
Drugs Produced at The Baxalta Facility in Covington
Baxalta (Bax from the name of its former parent company; alta a Latin adjective meaning 'high' or 'profound' ) is a biopharmaceutical company founded on 1 July 2015 after its parent company, Baxter International, spun off biopharmaceutical division. The company began its operation with a revenue of $6 billion, and is now a subsidiary of Takeda Pharmaceutical Company.
Details of The Baxalta Plasma-Based Treatment Complex in Covington
Phased Development of The Georgia-Based Facility
Baxalta’s Licensed Immunoglobulin Treatments
Marketing Commentary on Baxalta
Contractors Involved in The Project